A three-amino-acid peptide, Glu-Asp-Arg, from the Russian short-peptide bioregulator program, sold online for brain protection and anti-aging. Its evidence is cell and animal work from essentially one research group, plus a small uncontrolled study in 32 older patients. It is not approved anywhere.
Pinealon's proposed mechanism is unusual: its developers argue that a peptide this small can pass into the cell nucleus and bind histone proteins or nucleic acids, changing which genes are read. Molecular modeling found possible binding sites in the promoter regions of genes tied to cell death, antioxidant defense, and nerve growth, including CASP3, SOD2, and GAP43. In cell experiments it slowed the activation of the ERK signaling pathway and changed the cell cycle. The idea is inferred from computer models and cell cultures rather than demonstrated in a living brain.
Taken as a capsule (1/8)
Pinealon, a peptide of just 3 amino acids, is taken as a capsule.
Whatever the route, the measured effects are antioxidant and neuroprotective in a dish. In cerebellar granule cells, neutrophils, and PC12 cells it limited reactive oxygen species in a dose-dependent way and reduced necrotic death. In hippocampal neurons under amyloid toxicity it raised the number of mushroom-shaped dendritic spines by 71%, and in neurons made from the skin cells of elderly donors it increased dendritic branching and reduced oxidative DNA damage. Nothing shows the peptide reaches the human brain after a capsule or injection.
Pinealon is sold online for memory, brain aging, and neuroprotection. In laboratory studies it reduced reactive oxygen species and cell death in neurons and other cells under oxidative stress, restored dendritic spines in mouse hippocampal neurons exposed to amyloid, and prevented spine loss in a mouse model of Alzheimer's disease. The only human report is an uncontrolled study of 32 patients aged 41 to 83 with multiple chronic conditions and organic brain syndrome, which described an anabolic effect and slower biological aging but also a drop in blood stem cell markers. No controlled trial exists.
Its developers describe it as a bioregulator, a class of two to four amino acid peptides they say adjust gene activity in specific tissues. Products sold under this name have no verified identity or dose. No company outside the originating program is developing it, and no regulator has reviewed it. Regulators in Australia and Canada warn that unapproved peptide products sold online have not been assessed for safety, quality, or effectiveness.
The published work comes largely from one research program in Saint Petersburg. It includes cell studies of oxidative stress and neuronal spines, a mouse Alzheimer's model treated from 2 to 4 months of age, a study of fibroblast-derived induced neurons from elderly donors, and a 2015 Russian-language clinical report on 32 patients without a placebo group. Independent replication is limited. The 2020 mechanism paper is a review by the developers rather than new data.
Whether any laboratory effect occurs in people is unknown, since the human evidence is essentially absent. The claim that a tripeptide crosses into the nucleus and regulates genes rests on modeling rather than direct demonstration. The only human study hints at possible suppression of blood cell production, which no follow-up has examined. Until an independent controlled trial is run, marketing it for brain protection makes claims the evidence does not support.
No controlled safety data exist. The one human study, in 32 older patients, reported a significant fall in CD34-positive blood stem cell markers, which the authors read as inhibition of blood cell production, and it detected pro-oxidant activity on chemiluminescence testing despite the peptide's antioxidant reputation. The same authors nonetheless recommended it as a geroprotector. Products sold online add the risks of unknown identity, purity, and dose.
No regulator has approved this compound, and no company is seeking approval.
Pinealon is not approved by the FDA or any other regulator and has never been reviewed by any of them. It is sold as a research chemical or supplement-style product outside any drug quality system. Australia's TGA warns that unapproved peptide products promoted online for anti-aging and cognitive performance have not been evaluated for safety, quality, or effectiveness, and Health Canada warns that unauthorized injectable peptides are illegal to sell in Canada. No anti-doping or compounding listing specific to pinealon was found.